CAJ | 학술논문

目的观察小剂量吸入糖皮质激素(inhaled corticosteroids,ICS)联合小剂量茶碱对未控制吸烟支气管哮喘(简称哮喘)患者的治疗效果.方法筛选门诊未控制吸烟哮喘患者80例,随机分为试验组和对照组,试验组为吸烟患者,对照组为不吸烟患者.两组每日吸入布地奈德,每吸200 μg,每天2吸,联合口服氨茶碱片0.1g,每天3次,疗程3个月.比较治疗前后的哮喘控制测试(asthma controltest,ACT)评分,呼气峰流速(peak expiratory flow,PEF),第1秒用力呼气容积占预计值百分比(FEV1％pred),外周静脉血IL-4、IL-5、IgE值的变化.结果两组治疗前、治疗3个月后的ACT评分、PEF、FEV1％ pred、IL-4、IL-5、IgE值:试验组分别为:(14.3±2.4)和(21.7±2.0),(255.9±99.7) L/min和(290.3±105.2) L/min,(66.5±4.7)和(72.9±5.4),(14.5±3.2) ng/L和(12.3±3.4) ng/L,(27.2±6.4) ng/L和(24.2±5.8) ng/L,(82.7±16.8) IU/ml和(67.1±14.3) IU/ml,对照组分别为:(13.8±2.2)和(21.5±1.4),(279.1±103.3) L/min和(321.3±110.4)L/min,(68.8±5.8)和(74.8±5.5),(13.4±2.9) ng/L和(11.4±2.8) ng/L,(26.5±6.9) ng/L和(22.8±6.2) ng/L,(78.8±18.2) IU/ml和(66.4±17.8) IU/ml,两组组内比较差异有统计学意义(P＜0.05),组间比较差异无统计学意义(P＞0.05).结论小剂量ICS联合小剂量茶碱,在改善吸烟哮喘患者症状、提高肺功能、控制气道炎症方面与不吸烟患者有相同的疗效.
목적 관찰소제량흡입당피질격소(inhaled corticosteroids,ICS)연합소제량다감대미공제흡연지기관효천(간칭효천)환자적치료효과.방법 사선문진미공제흡연효천환자80례,수궤분위시험조화대조조,시험조위흡연환자,대조조위불흡연환자.량조매일흡입포지내덕,매흡200 μg,매천2흡,연합구복안다감편0.1g,매천3차,료정3개월.비교치료전후적효천공제측시(asthma controltest,ACT)평분,호기봉류속(peak expiratory flow,PEF),제1초용력호기용적점예계치백분비(FEV1％pred),외주정맥혈IL-4、IL-5、IgE치적변화.결과 량조치료전、치료3개월후적ACT평분、PEF、FEV1％ pred、IL-4、IL-5、IgE치:시험조분별위:(14.3±2.4)화(21.7±2.0),(255.9±99.7) L/min화(290.3±105.2) L/min,(66.5±4.7)화(72.9±5.4),(14.5±3.2) ng/L화(12.3±3.4) ng/L,(27.2±6.4) ng/L화(24.2±5.8) ng/L,(82.7±16.8) IU/ml화(67.1±14.3) IU/ml,대조조분별위:(13.8±2.2)화(21.5±1.4),(279.1±103.3) L/min화(321.3±110.4)L/min,(68.8±5.8)화(74.8±5.5),(13.4±2.9) ng/L화(11.4±2.8) ng/L,(26.5±6.9) ng/L화(22.8±6.2) ng/L,(78.8±18.2) IU/ml화(66.4±17.8) IU/ml,량조조내비교차이유통계학의의(P＜0.05),조간비교차이무통계학의의(P＞0.05).결론 소제량ICS연합소제량다감,재개선흡연효천환자증상、제고폐공능、공제기도염증방면여불흡연환자유상동적료효.
Objective To investigate the therapeutic effect of low-dose inhaled corticosteroids plus low-dose theophylline to the smokers with moderate bronchial asthma (asthma).Methods To screen 80 asthma cases in the clinic,and they were randomized to two groups:the observed group and the control group.The observed group consisted of smokers and the observed group consisted of non smokers.They all accepted inhalation budesonide 200 μg/d plus aminophylline tablet (0.1 gtid po) for 3 months.The ACT,PEF,FEV1 ％ predicted,IL-4,IL-5 and IgE of peripheral blood were compared before and after treatment.Results Before and 3 months after the treatment,the ACT,PEF,FEV1％ predicted,IL-4,IL-5,IgE value for the observed group were (14.3±2.4) and (21.7±2.0),(255.9±99.7) L/min and (290.3±105.2) L/min,(66.5±4.7) and (72.9±5.4),(14.5±3.2) ng/L and (12.3±3.4) ng/L,(27.2± 6.4) ng/L and (24.2±5.8) ng/L,(82.7 ± 16.8) IU/ml and (67.1 ± 14.3) IU/ml,respectively,and those for the control group were (13.8 ± 2.2) and (21.5 ± 1.4),(279.1 ± 103.3) L/min and (321.3±110.4) L/min,(68.8±5.8) and (74.8±5.5),(13.4±2.9) ng/L and (11.4±2.8)ng/L,(26.5±6.9) ng/L and (22.8± 6.2) ng/L,(78.8±18.2) IU/ml and (66.4±17.8) IU/ml,respectively,which were remarkably improved in both groups (P ＜ 0.05).There were no differences between two groups (P ＞0.05).Conclusions Compared with non-smokers,the smokers with moderate bronchial asthma treated with ICS plus low dose theophylline showed similar therapeutic effects in the improvement of clinical symptoms,increasing of lung function and control of the airway inflammation.